Journal of Clinical Pediatrics >
Advances in transplantation therapy in the treatment of type 1 diabetes in children and adolescents
Received date: 2022-02-28
Online published: 2022-05-13
Prevalence of type 1 diabetes in children and adolescents rises in decades of years. Medication could keep the serum level of glucose in a reasonable range rather than cure the disease. Transplantation, mainly islet transplantation, stem cell transplantation and pancreas transplantation, has attracted more attention for the possibility of curing type 1 diabetes. Rejection, islet inflammation and apoptosis hinder a successful transplantation, which may be relieved by carbon monoxide or regulatory T cell therapies. Most of studies about transplantation treatment for type 1 diabetes were on animals or adults, with few on children and adolescents. Furthermore, fecal microbiota transplantation could halt progression of human new-onset type 1 diabetes, which could be an adjuvant therapy in future days.
Key words： transplantation; child; adolescent; type 1 diabetes
Yao CHEN , Xiumin WANG . Advances in transplantation therapy in the treatment of type 1 diabetes in children and adolescents[J]. Journal of Clinical Pediatrics, 2022 , 40(5) : 334 -338 . DOI: 10.12372/jcp.2022.22e0253
| [1] | American Diabetes Association Professional Practice Committee, American Diabetes Association Professional Practice Committee, Draznin B, et al. Classification and diagnosis of diabetes: standards of medical care in diabetes-2022[J]. Diabetes Care, 2022, 45(Suppl 1): S17-S38. |
| [2] | Wherrett DK, Chiang JL, Delamater AM, et al. Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report[J]. Diabetes Care, 2015, 38(10): 1975-1985. |
| [3] | Chiang JL, Maahs DM, Garvey KC, et al. Type 1 diabetes in children and adolescents: A position statement by the American diabetes association[J]. Diabetes Care, 2018, 41(9): 2026-2044. |
| [4] | Chamberlain JJ, Kalyani RR, Leal S, et al. Treatment of type 1 diabetes: Synopsis of the 2017 American diabetes association standards of medical care in diabetes[J]. Ann Intern Med, 2017, 167(7): 493-498. |
| [5] | Gamble A, Pepper AR, Bruni A, et al. The journey of islet cell transplantation and future development[J]. Islets, 2018, 10(2): 80-94. |
| [6] | Chetboun M, Jannin A, Kerr-Conte J, et al. 1921-2021: From insulin discovery to islet transplantation in type 1 diabetes[J]. Ann Endocrinol (Paris), 2021, 82(2): 74-77. |
| [7] | Brooks AM, Oram R, Home P, et al. Demonstration of an intrinsic relationship between endogenous C-peptide concentration and determinants of glycemic control in type 1 diabetes following islet transplantation[J]. Diabetes Care, 2015, 38(1): 105-112. |
| [8] | Vantyghem MC, Raverdy V, Balavoine AS, et al. Continuous glucose monitoring after islet transplantation in type 1 diabetes: an excellent graft function (β-score greater than 7) Is required to abrogate hyperglycemia, whereas a minimal function is necessary to suppress severe hypoglycemia (β-score greater than 3)[J]. J Clin Endocrinol Metab, 2012, 97(11): E2078- E2083. |
| [9] | Shapiro AM, Pokrywczynska M, Ricordi C. Clinical pancreatic islet transplantation[J]. Nat Rev Endocrinol, 2017, 13(5): 268-277. |
| [10] | Dugbartey GJ. Carbon monoxide in pancreatic islet transplantation: A new therapeutic alternative to patients with severe type 1 diabetes mellitus[J]. Front Pharmacol, 2021, 12: 750816. |
| [11] | Marfil-Garza BA, Hefler J, Bermudez De Leon M, et al. Progress in translational regulatory T cell therapies for type 1 diabetes and islet transplantation[J]. Endocr Rev, 2021, 42(2): 198-218. |
| [12] | Tootee A, Nikbin B, Ghahary A, et al. Assessment of immune-alternations and their correlations with therapeutic outcomes of transplantation of autologous Mesenchymal and Allogenic fetal stem cells in patients with type 1 diabetes: a study protocol[J]. J Diabetes Metab Disord, 2021, 20(1): 1067-1073. |
| [13] | Lu J, Shen SM, Ling Q, et al. One repeated transplantation of allogeneic umbilical cord mesenchymal stromal cells in type 1 diabetes: an open parallel controlled clinical study[J]. Stem Cell Res Ther, 2021, 12(1): 340. |
| [14] | Voltarelli JC, Couri CE, Stracieri AB, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus[J]. JAMA, 2007, 297(14): 1568-1576. |
| [15] | Malmegrim KC, de Azevedo JT, Arruda LC, et al. Immunological balance is associated with clinical outcome after autologous hematopoietic stem cell transplantation in type 1 diabetes[J]. Front Immunol, 2017, 8:167. |
| [16] | Lindahl JP, Hartmann A, Horneland R, et al. Improved patient survival with simultaneous pancreas and kidney transplantation in recipients with diabetic end-stage renal disease[J]. Diabetologia, 2013, 56(6): 1364-1371. |
| [17] | Chudek J, Kolonko A, Ziaja J, et al. Beneficial effect of successful simultaneous pancreas-kidney transplantation on plasma profile of metalloproteinases in type 1 diabetes mellitus patients[J]. J Clin Med, 2021, 10(17): 3800. |
| [18] | Cho JA, Chinnapen DJF. Targeting friend and foe: Emerging therapeutics in the age of gut microbiome and disease[J]. J Microbiol, 2018, 56(3): 183-188. |
| [19] | Mariño E, Richards JL, McLeod KH, et al. Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes[J]. Nat Immunol, 2017, 18(5): 552-562. |
| [20] | de Groot P, Nikolic T, Pellegrini S, et al. Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial[J]. Gut, 2021, 70(1): 92-105. |
/
| 〈 |
|
〉 |
